Molecular Therapies in Thyroid Cancer
Thyroid cancer is a common diagnosis with greater than 34,000 cases per year in the United States. Early stage thyroid cancer is often managed with surgical intervention and radioactive iodine; however, for recurrent or metastatic disease, the treatment options, historically, have been limited to ch...
Main Authors: | Mark Agulnik, Timothy Huyck |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2010-12-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/4/1/91/ |
Similar Items
-
Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer
by: Prachi Mishra, et al.
Published: (2021-12-01) -
Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review
by: Mohammad Al-Jundi, et al.
Published: (2020-07-01) -
Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience
by: Matea Pešorda, et al.
Published: (2020-01-01) -
RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
by: Massimo Santoro, et al.
Published: (2020-04-01) -
Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities
by: Loredana Lorusso, et al.
Published: (2021-03-01)